NCT05763004 2024-10-08
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
ImmunOs Therapeutics AG
Phase 1 Unknown